Добро пожаловать в клуб

Показать / Спрятать  Домой  Новости Статьи Файлы Форум Web ссылки F.A.Q. Логобург    Показать / Спрятать

Главное меню
ДомойНовостиСтатьиДефектологияПостановка звуковФайлыКнижный мирФорумСловарьРассылкаКаталог ссылокРейтинг пользователейЧаВо(FAQ)КонкурсWeb магазинШкольникамЭлектроникаБыт.техникаКарта сайта

Поздравляем нового Логобуржца малиновка со вступлением в клуб!



Formulation and In Vitro Evaluation of Buccal Tablet of Famotidine   Jalpeshkumar Bhavsar,Mukesh Patel and Natvarlal Patel

Formulation and In Vitro Evaluation of Buccal Tablet of Famotidine

132 страниц. 2012 год.
LAP Lambert Academic Publishing
Famotidine is histamine –H2 receptor antagonist. It has bioavailability of 40 to 45% and it has shorter plasma half life of 2.5 to 3.5 hrs. The effective treatment of erosive esophagitis and Zolinger-Elisons syndrome requires administration of 20 mg of Famotidine 4 times a day. A conventional dose of 20 mg can inhibit gastric acid secretion up to 5 hours but not up to 10 hours. An alternative dose of 40 mg leads to plasma fluctuations; thus a sustained release dosage form of famotidine is desirable. Direct access to the systemic circulation bypasses drugs from the hepatic first pass metabolism leading to high bioavailability. Moreover, the buccal route is easily accessible, has a good patient compliance and can be used in patients who can’t swallow. Bilayer buccal tablet was prepared by using mucoadhesive polymer combination of Sodium CMC and Carbopol934P, by direct compression with backing layer of Ethyl cellulose. The optimized formulation F1 had given release of 102.57% in 8hrs...
- Генерация страницы: 0.04 секунд -